Navigation Links
NREL and Johnson Matthey announce 5-year collaboration on biofuels
Date:12/18/2012

iences and the principal investigator in the CRADA.

The non-food derived feedstocks used to produce the biofuels will vary from fast-growing poplar or pine trees to switch grass, forest and agriculture residue and municipal solid waste. It will not include anything that is actually food for humans.

The vapor produced from the pyrolysis of biomass can be used to make transportation fuel, if industry can efficiently convert it into the hydrocarbons similar to petroleum-based fuels used in modern engines.

Pyrolysis involves thermally decomposing organic materials using heat and pressure in the absence of oxygen. Although the pyrolysis vapors contain carbon that can be condensed into an oil, impurities in that condensed oil make it not suitable to be used in an engine or even readily converted into a fuel. This CRADA will develop catalytic materials that can convert these vapors into liquid fuels that can be use in cars, trucks, train engines and jets.

"The best outcome would be, in five years, to have a new catalytic process which can make gasoline, diesel, and jet fuel at a price range that is better than, or competitive with, the cost of existing fuels," Nimlos said.

If that happens, industry would face less risk in getting the financing necessary to scale up biofuels technologies, and the industry will move closer to producing hydrocarbon fuels from biomass for about $3 per gallon, which is a 2017 DOE goal.

Nimlos said the agreement means the two teams of experts will work together from the very beginning, when the experimental and testing scale is smallest. "We'll scale up the equipment, while Johnson Matthey develops and scales up the catalysts," he said. "By working together and sharing our expertise, we'll make a lot more progress."

Bolin agreed: "Together, we can make bigger and better strides."


'/>"/>
Contact: David Glickson
david.glickson@nrel.gov
303-275-4097
DOE/National Renewable Energy Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
3. ChromaDex® Announces Financial Results for the Year Ended 2011
4. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
5. MARC travel awards announced for EB 2012
6. MARC travel award announced for the 2012 ASCI/AAP Joint Meeting
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
9. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
10. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
11. Botanical institutions announce plans to create first online World Flora
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Mentor Award of the American Association for the Advancement ... education and research changes at his institution, leading to ... biological sciences." Tsin, who is a professor of ... Training in the Sciences at the University of Texas ...
... of Philadelphia (CHOP) have developed a unique laboratory ... molecules. The test relies on faster, more comprehensive ... (HLAs)--complex, highly variable proteins on cell surfaces that ... test may improve transplantation outcomes through a more ...
... , NEW YORK, NY (February 12, 2014) A ... by Wellington V. Cardoso, MD, PhD, has found the ... A deficiency and postnatal airway hyperresponsiveness, a hallmark of ... deficit of this essential vitamin while the lung is ...
Cached Biology News:2013 AAAS Lifetime Mentor Award goes to Andrew Tsin of the University of Texas at San Antonio 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3Prenatal vitamin A deficiency tied to postnatal asthma 2Prenatal vitamin A deficiency tied to postnatal asthma 3
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... PHILADELPHIA, May 28 Premier Research Group plc ... of Anthony Faragasso, MD as Executive Director and ... position, Dr. Faragasso will lead,the global Medical Management ... and safety services, Dr. Faragasso brings to ...
... ... Manufacturing Experience -, SAN DIEGO, May 28 ... Gordon H.,Busenbark to the company,s board of directors. Mr. Busenbark ... privately,held development-stage specialty pharmaceuticals company focused on,diseases of the central ...
... launch of a new collaborative website initially focusing on ... WikiProfessional technology underlying the site has been developed based ... open access journal Genome Biology, WikiProteins provides a method ... The article is written by Barend Mons of the ...
Cached Biology Technology:Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety 2Nventa Appoints Gordon H. Busenbark to Board of Directors 2Large-scale community protein annotation -- WikiProteins 2
...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
... immunostaining ,This solution has effect on enhancing ... clearer signal than the one obtained by ... of secondary antibody used and exposure time ... have images with high S/N ratio and ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Biology Products: